Imexpharm EBIT/Assets
The Operating Income to Assets Ratio (EBIT/Assets) of Imexpharm (IMP.VN) as of Sep 10, 2026 is 16.62 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 16.58 % — a change of 0.24% (higher).
Get this data via API
Financial Data API
EBIT/Assets
16.62 %
YoY
0.24%
Last updated:
The Imexpharm EBIT/Assets history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT/Assets | YoY |
|---|---|---|
| 16.62 % | +0.24% | |
| 16.58 % | +4.10% | |
| 15.93 % | +22.30% | |
| 13.02 % | +20.76% | |
| 10.78 % | -13.90% | |
| 12.52 % | +13.93% | |
| 10.99 % | +23.13% | |
| 8.93 % | +22.64% | |
| 7.28 % | -29.52% | |
| 10.33 % | +6.12% | |
| 9.73 % | -1.48% | |
| 9.88 % | — |
Imexpharm Stock analysis
Frequently Asked Questions about Imexpharm stock
Operating Income to Assets Ratio (EBIT/Assets) of Imexpharm is 16.62 % in 2026.
Operating Income to Assets Ratio (EBIT/Assets) of Imexpharm changed from 16.58 % to 16.62 %, representing a 0.24% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Imexpharm since 2006 – with annual values, charts, and detailed analysis.
EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Imexpharm with sector peers and the industry average to assess whether it is attractive.
To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).
Profitability — Imexpharm
All Key Metrics — Imexpharm
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth